Compass Therapeutics (CMPX) Common Equity (2018 - 2026)

Compass Therapeutics has reported Common Equity for 9 years, with the latest figure at $186.5 million in Q1 2026.

• Quarterly Common Equity rose 69.09% year-over-year to $186.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.5 million (up 69.09% YoY) and the FY2025 annual result came in at $196.8 million, up 57.14% from the prior year.
• Common Equity declined to $186.5 million in Q1 2026 per CMPX's latest filing, from $196.8 million in the prior quarter.
• Over five years, Common Equity peaked at $209.6 million in Q3 2025 and troughed at $93.2 million in Q2 2025.
• A 5-year average of $151.4 million and a median of $148.5 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 386.09% in 2022, then sank 36.21% in 2025.
• Over 5 years, Common Equity stood at $181.6 million in 2022, then fell by 18.22% to $148.5 million in 2023, then decreased by 15.69% to $125.2 million in 2024, then jumped by 57.14% to $196.8 million in 2025, then decreased by 5.24% to $186.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $186.5 million, $196.8 million, and $209.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.